Fig. 2

Mean Change From Baseline in Overall BASDAI and Modified BASDAI (Excluding Question 3) Scores, and Proportion of Patients Achieving BASDAI50, at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). Mean change from baseline in the overall BASDAI score (A) or modified BASDAI (excluding question 3—How would you describe the overall level of pain/swelling in joints other than neck, back, or hips you have had?) score (C) at weeks 12 and 24 for PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1. Mean change from baseline in overall BASDAI (B) or modified BASDAI (D) at weeks 12 and 24 for PsA patients with axial involvement defined by either criterion treated with placebo or upadacitinib 15 mg QD from SELECT-PsA 2. Proportions of PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria that achieved BASDAI50 at weeks 12 and 24 treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1 (E) or with placebo or upadacitinib 15 mg QD from SELECT-PsA 2 (F). Overall BASDAI and modified BASDAI were analyzed using mixed-effect model for repeated measures and are shown as least squares means with 95% CIs. BASDAI50 was analyzed using Cochran-Mantel–Haenszel tests with non-responder imputation and shown as response rates with 95% CIs. ****P < 0.0001, ***P < 0.001, *P < 0.05 upadacitinib 15 mg versus placebo; ^#P < 0.05, upadacitinib 15 mg versus adalimumab; nominal P values are shown and were not multiplicity controlled. ADA, adalimumab; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI50, ≥ 50% improvement from baseline in BASDAI; bDMARD, biologic disease-modifying antirheumatic drug; CI, confidence interval; EOW, every other week; IR, inadequate response; PBO, placebo; PRO, patient-reported outcome; PsA, psoriatic arthritis; QD, once daily; UPA, upadacitinib